As a high-tech company developing blue-ocean biologics with its AI and big data platforms, GBB has built technical service centers and owns self-developed blue-ocean products. For example, the rhEPO-Fc project that is to be license-out has entered the clinical phase I. The teriparatide and exenatide projects have completed clinical phase III and have been successfully licensed-out. Meanwhile, GBB is developing many disruptive innovative molecules and dosage forms for diseases including diabetes, osteoporosis, blood diseases, and ophthalmological diseases.